
    
      Subjects who took part in GWMS0001 Part A were invited to continue to receive GW-1000-02 in
      this four-week open-label part of the study. Subjects received open-label cannabinoid extract
      (GW-1000-02) for four weeks, either with or without peppermint flavouring, according to their
      study centre. Subjects who completed the study could choose to continue receiving GW-1000-02
      by entering the long-term safety extension follow-on study.
    
  